Dr. Victoria Hale is a pharmaceutical scientist and executive. Her passion is the reduction of health inequities through the development of cures for the most significant public/global health needs. She founded two nonprofit pharmaceutical companies, OneWorld Health (2000, OWH) and Medicines360 (2009, M360), and was the CEO of each for many years. OWH was the first nonprofit pharmaceutical company in the US. OWH developed a new cure for visceral leishmaniasis, and developed a platform technology to reduce the cost of malaria drugs by more than 10-fold. M360 has developed and obtained FDA approval of a hormonal IUD (intrauterine device) for contraception in women all around the globe. Dr. Hale established her expertise in all stages of biopharmaceutical drug development at the US Food and Drug Administration (FDA), and at Genentech. She earned her PhD in Pharmaceutical Chemistry from UCSF, where she presently maintains an Adjunct Professorship in Bioengineering & Therapeutic Sciences. She was elected to membership in the Institute of Medicine of the US National Academies, and was granted the MacArthur “Genius” Award. She received the President’s Award of Distinction from the American Association of Pharmaceutical Scientists. Dr. Hale is internationally recognized as a senior social entrepreneur by the Skoll Foundation, Schwab Foundation, and Ashoka. The Economist named Victoria Hale the recipient of its Social and Economic Innovation Award.
Clean Water • Health • Health Delivery • Human Rights • Peace • Women's and Girls' Education
Central and Southern Asia, North America
